Sardocor (Medera Biopharma)

AAV1/SERCA2a gene therapy for heart failure

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
SERCA2a (gene therapy)Gene therapy / editing
Heart Failure

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.